Minimally Invasive Brain Science (02172) issued an announcement. In the year ended December 31, 2023, it is expected that the Group will...
Zhitong Finance App News, Minimally Invasive Brain Science (02172) announced that during the year ended December 31, 2023, the Group is expected to achieve adjusted net profit of not less than RMB 178 million, an increase of at least 36% over the year ended December 31, 2022. Compared with the net loss of RMB 24.68 million in the previous year, the Group is expected to turn net profit into profit and grow strongly during the reporting period.
The Board believes that the aforementioned sharp increase in the Group's profit expectations is mainly due to the following reasons: various market-share leading products (including Tubridge)Blood flow-guided dense mesh stents, BridgeVertebral artery rapamycin targeted elution stent system and NUMEN(Detachable embolic springs, etc.) Continue to explore empty hospitals and sinking markets, further consolidate competitive advantages, and achieve significant revenue growth; newly approved products in 2022 (including Neurohawkintracranial embolization stent, DiveerIntracranial balloon dilatation catheters, etc.) accelerate hospital access and contribute to the Group's revenue growth; through implementing supply chain improvements and cost saving measures, the Group continues to improve gross margin levels and operational efficiency, and profitability has been significantly enhanced.